TM6SF2 and metabolic dysfunction-associated steatotic liver disease: The E167K variant of transmembrane 6 superfamily member 2 (TM6SF2) decreases the secretion of very low-density lipoprotein (VLDL) to favor hepatic fat accumulation in NAFLD patients but confers cardiovascular protection by reducing the amount of circulating lipids [19, 20].